95 related articles for article (PubMed ID: 9679953)
1. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate.
Farina AR; Tacconelli A; Teti A; Gulino A; Mackay AR
Cancer Res; 1998 Jul; 58(14):2957-60. PubMed ID: 9679953
[TBL] [Abstract][Full Text] [Related]
2. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism.
Monea S; Lehti K; Keski-Oja J; Mignatti P
J Cell Physiol; 2002 Aug; 192(2):160-70. PubMed ID: 12115722
[TBL] [Abstract][Full Text] [Related]
3. Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain.
Farina AR; Cappabianca L; Di Ianni N; Ruggeri P; Ragone M; Merolle S; Gulino A; Mackay AR
FEBS Lett; 2012 Jul; 586(16):2366-74. PubMed ID: 22677171
[TBL] [Abstract][Full Text] [Related]
4. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase.
Bigg HF; Morrison CJ; Butler GS; Bogoyevitch MA; Wang Z; Soloway PD; Overall CM
Cancer Res; 2001 May; 61(9):3610-8. PubMed ID: 11325829
[TBL] [Abstract][Full Text] [Related]
5. IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression.
Stearns ME; Fudge K; Garcia F; Wang M
Invasion Metastasis; 1997; 17(2):62-74. PubMed ID: 9561025
[TBL] [Abstract][Full Text] [Related]
6. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.
Jo Y; Yeon J; Kim HJ; Lee ST
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):511-9. PubMed ID: 10642509
[TBL] [Abstract][Full Text] [Related]
7. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2.
Deryugina EI; Bourdon MA; Reisfeld RA; Strongin A
Cancer Res; 1998 Aug; 58(16):3743-50. PubMed ID: 9721888
[TBL] [Abstract][Full Text] [Related]
8. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line.
Lombard MA; Wallace TL; Kubicek MF; Petzold GL; Mitchell MA; Hendges SK; Wilks JW
Cancer Res; 1998 Sep; 58(17):4001-7. PubMed ID: 9731514
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells.
Janowska-Wieczorek A; Marquez LA; Matsuzaki A; Hashmi HR; Larratt LM; Boshkov LM; Turner AR; Zhang MC; Edwards DR; Kossakowska AE
Br J Haematol; 1999 May; 105(2):402-11. PubMed ID: 10233411
[TBL] [Abstract][Full Text] [Related]
11. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).
Worley JR; Thompkins PB; Lee MH; Hutton M; Soloway P; Edwards DR; Murphy G; Knäuper V
Biochem J; 2003 Jun; 372(Pt 3):799-809. PubMed ID: 12630911
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line.
Lu KV; Jong KA; Rajasekaran AK; Cloughesy TF; Mischel PS
Lab Invest; 2004 Jan; 84(1):8-20. PubMed ID: 14631378
[TBL] [Abstract][Full Text] [Related]
13. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
Emenaker NJ; Basson MD
J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
[TBL] [Abstract][Full Text] [Related]
14. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
15. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
16. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
17. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy.
Webster L; Chignell AH; Limb GA
Exp Eye Res; 1999 Jan; 68(1):91-8. PubMed ID: 9986746
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract][Full Text] [Related]
19. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma.
Kugler A; Hemmerlein B; Thelen P; Kallerhoff M; Radzun HJ; Ringert RH
J Urol; 1998 Nov; 160(5):1914-8. PubMed ID: 9783985
[TBL] [Abstract][Full Text] [Related]
20. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.
Hitchon CA; Danning CL; Illei GG; El-Gabalawy HS; Boumpas DT
J Rheumatol; 2002 Jan; 29(1):107-17. PubMed ID: 11824946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
